Montanide ISA 720 is more effective than BCG as an adjuvant Leishmania killed vaccine in BALB/c mice

International Journal of Integrative Biology

Volumn 7, Issue 2, 2009, Pages 107-116

  Mutiso, Joshua M ^a,b   Macharia, John C ^a   Kariuki, Thomas M ^a   Gicheru, Michael M ^b  

^a INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

Author keywords

Adjuvants; Alum; BALB c mice; BCG; Cutaneous leishmaniasis; Immune responses; KLM; Montanide ISA 720; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; BCG VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LEISHMANIA VACCINE; MONTANIDE ISA 720; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; IMMUNOGENICITY; LEISHMANIA; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PROMASTIGOTE; SKIN DEFECT; SKIN LEISHMANIASIS;

LEISHMANIA MAJOR; MUS; PRIMATES;

EID: 74549123922     PISSN: 09738363     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Abdelhak S, Louzir H, et al. (1995) Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiol., 141(7): 1585-1592.
2. Alimohammadian MH, Darabi H, et al. (2002) Adjuvant Effect of Leishmania majorPromastsgotes on the Immune Response of Mice to Ovalbumin. Iran Biomed. J., 6(4): 123-128.
3. Alving CR (2002) Design and selection of vaccine adjuvants: animal models and human trials. Vaccine, 20(3): 56-64.
4. Araujo Z, Ayachi EB, et al. (1999) Vaccination of mice with a combination of BCG and killed Leishmania promastigotes reduces acute Trypanosoma cruzi infection by promoting an IFN-γ response. Vaccine, 17(7-8): 957-964.
5. Bahar K, Dowlati Y, et al. (1996) Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clinics in dermatology. New York: Elsevier. 14(5): 489-495.
6. Bomford R (1989) Aluminium salts: perspectives in their use as adjuvants. In: Immunological Adjuvants and Vaccines. NATO ASI Series A: Life sciences Vol. 179. Proceedings of a NATO Advanced Study Institute on Immunological Adjuvants and Vaccines, 24 June-5 July 1988, Cape Sounion Beach, Greece. Plenum Press. New York, pp: 35-41.
7. Buffet PA, Sulahian A, et al. (1995) Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrobial Agents Chemother., 39(9) 2167-2168.
8. Cabrera M, Jenefer MB, et al. (2000) Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasit. Immunol., 22(2): 73-79.
9. Collins WE, Barnwell JW, et al. (2006) Assessment of transmission-blocking activity of candidate pvs25 vaccine using gametocytes from chimpanzees. Am. J. Trop. Med. Hyg., 74(2): 215-221.
10. Convit J, Castellanos PI, et al. (1989) Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J. Infect. Dis., 160(1): 104-115.
11. Cook JA and Holbrook TW (1993) Immunogenicity of soluble and particulate antigens from Leishmania donovani: Effect of glucan as an adjuvant. Infect. Immun., 40: 1038-1043.
12. Eickhoff TC and Mayers M (2002) Workshop summary: Aluminium in vaccines. Vaccine, 20(Suppl 3): S1-4.
13. Gicheru MM, Olobo JO, et al. (1995) Visceral leishmaniasis in Vervet Monkeys: Immunological responses during asymptomatic infections. Scand. J. Immunol., 41(2): 202-208.
14. Gomez CE, Navea L, et al. (1999) The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates. Vaccine, 17(18): 2311-9.
15. Guirges SY (1971) Natural and experimental re-infection of man with Oriental sore. Ann. Trop. Med. Parasitol., 65(2): 197-205.
16. Hersey P. Menzies SW, et al. (2005) Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol. Immunother., 54: 208-218.
17. Holbrook TW and Cook JA (1983) Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes. Am. J. Trop. Med. Hyg., 32: 51-53.
18. Kaslow DC, Ian BC, et al. (1994) Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun., 62: 5576-5580.
19. Kenney RT and Edelman R (2003) Survey of human-use adjuvants. Expert Rev Vaccines, 2: 167-188.
20. Kenney RT, Sacks DL, et al. (1999) Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol., 163: 4481-4488.
21. Khalil EAG, Hassan EI, et al. (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in sudan. Lancet, 356(9240): 1565-1569.
22. Khamesipour A, Rafat S, et al. (2006) Leishmaniasis vaccine candidates for development: A global overview. Indian J. Med. Res,, 123: 423-438.
23. Liew FY, Millott S, et al. (1989) Macrophage activation by interferon-γ from host protective T cells is inhibited by IL-3 and IL-4 produced by disease promoting T cells in Leishmaniasis. Eur. J. Immunol., 19(7): 1227-1232.
24. Macharia JC, Bourdichon AJ., et al. (2004) Efficacy of trypan: a diminazene based drug as antileishmanial agent. Acta Trop., 92(3): 267-272.
25. Masina S, Gicheru MM, et al. (2003) Fasel NJ. Protection against cutaneous leishmaniasis in outbred Vervet Monkeys, using a recombinant Histone-1 antigen. J. Infect. Dis., 188(8): 1250-1257.
26. Misra A, Anuragha D, et al. (2001) Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine, 19(25-26): 3485-3492.
27. Modabber F (1995) Vaccines against leishmaniasis. Ann Trop Med Parasitol., 89(Suppl 1): 83-88.
28. Moll H and Martin R (1990) Resistance to murine cutaneous leishmaniasis is mediated by T H 1 cells, but disease-promoting CD4+ cells are different from TH2 cells. Eur. J. Immunol., 20(9): 2067-2074.
29. Momeni AZ, Jalayer T, et al. (1999) A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine, 17(5): 466-472.
30. Myriam A, Angelica C, et al. (2005) Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the plasmodium vivax duffy binding protein in Aotus monkeys. Am. J. Trop. Med. Hyg.,73(Suppl 5): 25-31.
31. Norman WB, William E, et al. (2002) Aluminium salts in vaccines-US perspective. Vaccine, 20(3): 18-23.
32. Oliveira GA, Kristiane W, et al. (2005) Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant montanide ISA 720 in a phase I trial. Infect. Immun., 73(6):3585-3597.
33. Olobo JO, Reid GDF, et al. (1992) IFN-γ and delayed type hypersensitivity are associated with cutaneous leishmaniasis in vervet monkeys following secondary rechallenge with Leishmania major Scand. J. Immunol., 36(suppl 11):48-52.
34. Scott P, Patricia N, et al. (1988) Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med., 168(5): 1675-1684.
35. Serebryakov VA, Karakhodznaeva SKH, et al. (1972) Effect of leishmanial vaccinations on the dynamics of immunity to diphteria in conditions of secondary revaccination with adsorbed pertussis-diphteria-tetanus vaccine. Med. Parasit. Mosk., 41(3): 303-309.
36. Shanfi I, FeKri AR, et al. (1998) Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet, 351: 1540-1543.
37. Smrkovski LL and Larson CL (1977) Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect. Immun.,. 16(1): 249-257.
38. Sohrabi Y, Mahmoud RJ, et al. (2005) Evaluation of immune response against leishmaniasis in resistance C57 BL/6 mice immunized with liposomes containing autoclaved Leishmania major with BCG. Cell Mol. Biol. Lett., 10: S98.
39. Solbach W, Forberg K, et al. (1986) Effect of T-Lymphocyte suppression on the parasite burden in Leishmania major-infected, genetically susceptible BALL/c Mice. Infect. Immunol., 54: 909-912.
40. Stacey KJ and Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun., 67(8): 3719-3726.
41. Sypek JP, Chung CL, et al. (1993) Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med., 177: 1797-1802.
42. Titus RG, Marchand M, et al. (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasit. Immunol., 7: 545-555.
43. Toledo H, Alberto B, et al. (2001) A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine, 19: 4328-4336.
44. Tonui WK, Mejia JS, et al. (2004) Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with Leishmania major. Infect. Immun., 72: 5654-5661.